# Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

> **NCT01341834** · PHASE1 · UNKNOWN · sponsor: **National Cancer Centre, Singapore** · enrollment: 49 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour

## Interventions

- **DRUG:** LBH589 and RAD001

## Key facts

- **NCT ID:** NCT01341834
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-03
- **Primary completion:** 2016-06
- **Final completion:** 2018-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2018-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01341834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01341834, "Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01341834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*